Balance Sheet Vanda Pharmaceuticals Inc.
Equities
VNDA
US9216591084
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.390 USD | +3.65% |
|
+0.56% | +12.53% |
| 12-04 | Vanda Says FDA Lifts Partial Hold on Tradipitant Motion-Sickness Study | MT |
| 12-04 | FDA Lifts Hold on Vanda Pharmaceuticals' Motion Sickness Drug | DJ |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash And Equivalents | 61.03M | 52.07M | 135M | 136M | 102M | |||||
Short Term Investments | 307M | 381M | 332M | 252M | 272M | |||||
Total Cash And Short Term Investments | 368M | 433M | 467M | 388M | 375M | |||||
Accounts Receivable, Total | 30.04M | 32.47M | 33.51M | 34.16M | 47.1M | |||||
Total Receivables | 30.04M | 32.47M | 33.51M | 34.16M | 47.1M | |||||
Inventory | 1.28M | 1.02M | 1.19M | 1.36M | 1.73M | |||||
Prepaid Expenses | 10.03M | 12M | 17.73M | 9.17M | 15.42M | |||||
Restricted Cash | 57K | - | - | - | - | |||||
Other Current Assets, Total | - | - | - | - | - | |||||
Total Current Assets | 409M | 478M | 519M | 433M | 439M | |||||
Gross Property Plant And Equipment | 22.62M | 21.76M | 21.39M | 20.32M | 24.24M | |||||
Accumulated Depreciation | -8.03M | -9.38M | -10.42M | -11.18M | -11.57M | |||||
Net Property Plant And Equipment | 14.6M | 12.38M | 10.97M | 9.14M | 12.68M | |||||
Other Intangibles, Total | 21.56M | 20.08M | 18.56M | 121M | 114M | |||||
Deferred Tax Assets Long-Term | 81.52M | 74.88M | 74.04M | 75M | 81.44M | |||||
Other Long-Term Assets, Total | 6.64M | 8.15M | 11.38M | 9.98M | 9.1M | |||||
Total Assets | 533M | 594M | 634M | 648M | 656M | |||||
Liabilities | ||||||||||
Accounts Payable, Total | 1.05M | 925K | 12.69M | 7.14M | 3.5M | |||||
Accrued Expenses, Total | 27.99M | 31.2M | 30.53M | 28.92M | 31.32M | |||||
Current Portion of Leases | 2.12M | 2.31M | 2.33M | 2.4M | 4.27M | |||||
Other Current Liabilities | 34.78M | 39.98M | 45.88M | 49.24M | 60.9M | |||||
Total Current Liabilities | 65.94M | 74.42M | 91.44M | 87.7M | 99.98M | |||||
Long-Term Leases | 11.5M | 10.06M | 8.81M | 7.01M | 8.09M | |||||
Deferred Tax Liability Non Current | - | - | - | - | - | |||||
Other Non Current Liabilities | 2.76M | 4.39M | 6.8M | 8.83M | 9.59M | |||||
Total Liabilities | 80.19M | 88.86M | 107M | 104M | 118M | |||||
Common Stock, Total | 55K | 56K | 57K | 58K | 58K | |||||
Additional Paid In Capital | 650M | 669M | 686M | 700M | 713M | |||||
Retained Earnings | -197M | -164M | -158M | -155M | -174M | |||||
Comprehensive Income and Other | 239K | -175K | -1.19M | -30K | 74K | |||||
Total Common Equity | 453M | 505M | 527M | 545M | 539M | |||||
Total Equity | 453M | 505M | 527M | 545M | 539M | |||||
Total Liabilities And Equity | 533M | 594M | 634M | 648M | 656M | |||||
Supplemental Items | ||||||||||
ECS Total Shares Outstanding on Filing Date | 54.88M | 55.91M | 56.79M | 57.54M | 58.32M | |||||
ECS Total Common Shares Outstanding | 54.87M | 55.9M | 56.78M | 57.53M | 58.31M | |||||
Book Value / Share | 8.26 | 9.03 | 9.28 | 9.47 | 9.24 | |||||
Tangible Book Value | 432M | 485M | 509M | 424M | 424M | |||||
Tangible Book Value Per Share | 7.87 | 8.67 | 8.96 | 7.36 | 7.28 | |||||
Total Debt | 13.61M | 12.37M | 11.14M | 9.4M | 12.36M | |||||
Net Debt | -354M | -420M | -456M | -379M | -362M | |||||
Debt Equivalent Oper. Leases | 21.6M | 21.6M | 20.8M | 20.8M | 21.19M | |||||
Account Code - Inventory Valuation | 5 | 5 | 5 | 5 | 5 | |||||
Inventories - Work In Process, Total | 66K | 30K | 23K | 27K | - | |||||
Inventories - Finished Goods, Total | 1.21M | 995K | 1.17M | 1.33M | 1.73M | |||||
Machinery, Total | 6.71M | 7.03M | 7.58M | 7.78M | 8.23M | |||||
Full Time Employees | 292 | 278 | 290 | 203 | 368 | |||||
Accumulated Allowance for Doubtful Accounts (Supple) | - | - | - | - | - |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















